For a total. ANDA 91105, held by Novast Labs Ltd. Ethinyl Estradiol; Norgestrel.
As of Nov 16, 2026, ANDA 91105 (Elinest), held by Novast Labs Ltd, was first approved by FDA on Mar 28, 2012, with 2 approved supplements and 0 published complete response letters.
INDICATIONS AND USAGE ELINEST TM is indicated for use by females of reproductive potential to prevent pregnancy. In a study of 1,287 women with a total of 11,085 cycles or 852.7 women-years of usage, the pregnancy rate in women age 15 to 40 years was approximately 1 pregnancy per 100 women-years of use.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Mar 28, 2012 | Original application | Approved | None posted |
| Product | Active ingredient | Marketing |
|---|---|---|
| Elinest0.03MG;0.3MG · tablet;oral-28 | Ethinyl Estradiol; Norgestrel | Rx |
| Jul 10, 2026 | Supplement 6Labeling · Standard review | Approved | None posted |
| Aug 9, 2017 | Supplement 2Labeling · Standard review | Approved | None posted |
| Mar 28, 2012 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters